G B Baretton
Overview
Explore the profile of G B Baretton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schagdarsurengin U, Luo C, Slanina H, Sheridan D, Fussel S, Bogurcu-Seidel N, et al.
Clin Epigenetics
. 2021 Nov;
13(1):211.
PMID: 34844636
Background: Ten-eleven translocation methylcytosine dioxygenase 1 (TET1) is involved in DNA demethylation and transcriptional regulation, plays a key role in the maintenance of stem cell pluripotency, and is dysregulated in...
2.
Rocken C, Baretton G, Kreipe H, Kirchner T
Pathologe
. 2017 Apr;
38(4):324-330.
PMID: 28432389
No abstract available.
3.
Baretton G, Aust D
Pathologe
. 2017 Feb;
38(2):93-97.
PMID: 28213714
Gastric cancer is still a relevant malignant disease with high morbidity and mortality. Current molecular genetic data show that gastric cancer, as other solid tumors as well, is not a...
4.
5.
Lordick F, Al-Batran S, Hofheinz R, Lorenzen S, Thuss-Patience P, Baretton G, et al.
Z Gastroenterol
. 2016 Aug;
54(8):791-6.
PMID: 27529529
Valid HER2 testing is essential for optimal therapy of patients with HER2 positive gastric cancer and the correct use of first-line treatment. While each breast cancer is routinely being tested...
6.
Muders M, Baretton G
Pathologe
. 2015 Sep;
36 Suppl 2:185-8.
PMID: 26395891
Disseminated tumor cells require a special microenvironment to form metastases. This metastatic niche is organ specific and forms prior to the establishment of visible metastases. The niche is characterized by...
7.
Tannapfel A, Aust D, Baretton G, Blaker H, Esposito I, Langner C, et al.
Pathologe
. 2015 Apr;
36(2):182-5.
PMID: 25855462
No abstract available.
8.
Keck B, Wach S, Taubert H, Zeiler S, Ott O, Kunath F, et al.
Int J Cancer
. 2014 May;
136(2):443-51.
PMID: 24862180
The standard treatment for invasive bladder cancer is radical cystectomy. In selected patients, bladder-sparing therapy can be performed by transurethral resection (TURBT) and radio-chemotherapy (RCT) or radiotherapy (RT). Our published...
9.
10.
Singer A, Deuse Y, Koch U, Holscher T, Pfitzmann D, Jakob C, et al.
Strahlenther Onkol
. 2012 Nov;
188(12):1125-32.
PMID: 23128896
Purpose: Studies have shown that GIPC1/Synectin is an essential adaptor protein of receptors that play an important role in cancer progression and therapy resistance. This is the first study to...